BioLife to Present Oral Peptide Technology in London
BioLife Products Limited will showcase its oral delivery platform for peptide medicines at the LSX Investival Showcase on November 16, 2026.
Updated on Nov. 3, 2026 in Diabetes
BioLife Products Limited will present its oral peptide delivery technology at the LSX Investival Showcase during London Life Sciences Week, with the presentation scheduled for November 16, 2026, at Old Billingsgate in London. The technology uses a dissolvable effervescent tablet to create a buffered solution and is not approved for the treatment of any disease.
Why it matters
The company's technology is designed to help protect peptide medicines during gastrointestinal transit to support systemic delivery, an approach that could expand options for peptide-based treatments. Its U.S. patent includes claims covering multiple GLP-1 receptor agonists, including semaglutide.
Preclinical studies have shown measurable systemic semaglutide exposure after oral administration, based on early laboratory research rather than approved clinical use. The granted U.S. patent protection extends into 2042, but whether the approach will reach patients remains unconfirmed.
The players
BioLife Products Limited
A company developing oral delivery technologies for peptide medicines, focused on enabling systemic absorption of drugs typically given by injection.
Dr. Farid Bennis
The founder and inventor of the BioLife technology, who has spent two decades researching oral peptide delivery.
The details
Founder Dr. Farid Bennis developed the technology, which combines over 35 years of pharmaceutical effervescence expertise with two decades of oral peptide research. The approach relies on a dissolvable effervescent tablet that forms a buffered solution intended to protect peptides as they pass through the gastrointestinal tract.
Timeline
- November 16, 2026, 3:15 to 3:30 p.m. GMT: BioLife presentation at the LSX Investival Showcase, Old Billingsgate, London
- 2042: Expected extent of U.S. patent protection
Big Picture
The presentation extends earlier human clinical research on oral insulin formulations to a broader class of peptide medicines, though the findings still require further validation. Oral delivery of injectable peptides has long been a goal in diabetes and obesity drug development.
For people managing diabetes or obesity, a successful oral route for GLP-1 drugs could mean taking medication as a pill instead of by injection. The technology remains in development, so no change to current treatment is available yet.
The takeaway
Oral delivery of peptide medicines is an active area of research, and readers should watch for clinical results before expecting new treatment options. Anyone considering medication changes should consult a healthcare provider.
What happens next
BioLife will present its oral peptide delivery technology at the LSX Investival Showcase on November 16, 2026, from 3:15 to 3:30 p.m. GMT at Old Billingsgate in London.
Further reading
Explore more on Diabetes to see how oral peptide therapies are being developed for blood sugar and weight management.
